Reações cutâneas provocadas por imunomoduladores injetáveis no tratamento de esclerose múltipla e fatores associados

Lígia Nogueira Manso Oliveira; Hélio Amante Miot; Tais Lopes Saranholi; Luciana Patrícia Fernandes Abbade

doi:10.5216/ree.v27.76957

Autores

Lígia Nogueira Manso Oliveira Universidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Botucatu, São Paulo, Brasil. E-mail: lg-nm@hotmail.com. https://orcid.org/0000-0003-4884-7406
Hélio Amante Miot Universidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Botucatu, São Paulo, Brasil. E-mail: heliomiot@gmail.com. https://orcid.org/0000-0002-2596-9294
Tais Lopes Saranholi Universidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Botucatu, São Paulo, Brasil. E-mail: tais.saranholi@gmail.com. https://orcid.org/0000-0002-2397-0646
Luciana Patrícia Fernandes Abbade Universidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Botucatu, São Paulo, Brasil. E-mail: fernandes.abbade@unesp.br. https://orcid.org/0000-0002-0334-2079

DOI:

https://doi.org/10.5216/ree.v27.76957

Palavras-chave:

Esclerose Múltipla, Hipersensibilidade, Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos

Resumo

Objetivos: descrever as reações cutâneas provocadas por imunomoduladores injetáveis utilizados no tratamento da esclerose múltipla e fatores associados. Métodos: estudo descritivo analítico transversal, observacional foi realizado com amostra não probabilística envolvendo pacientes com esclerose múltipla (EM) em tratamento ambulatorial. A coleta de dados foi realizada por meio de entrevista estruturada, guiada por dois instrumentos. Resultados: foram incluídos 116 participantes, com predomínio do sexo feminino (72,4%), idade média de 39,8 anos, cor branca (98,3%). A forma clínica da EM mais prevalente foi do tipo remitente recorrente (70,0%). Ocorreram uma ou mais reaçõescutâneas no local da aplicação do imunomodulador injetável em 101 (87,0%) participantes. As principais reaçõesforam: hiperemia (n = 86; 74%), esclerose (n= 68; 59%), equimose (n = 59; 51%), edema (n = 53; 46%) e calor (n = 50; 43%). A maior parte das reações foram consideradas de intensidade leves a moderadas. Os fatores associados àocorrência de reações foram depressão (p = 0,01) e Índice de Massa Corporal compatível com obesidade (p = 0,04). Conclusão: reações cutâneas no local de aplicação de imunomoduladores para tratamento de EM ocorrem em parcela considerável de pacientes e sua presença está associada a depressão e obesidade.

Downloads

Não há dados estatísticos.

Referências

Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019 Oct 9;26(1):27-40. https://doi.org/10.1111/ene.13819

Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L. Epidemiology of multiple sclerosis in Iran: a systematic review and meta-analysis. PLoS One. 2019 Apr 9;14(4):e0214738. https://doi.org/10.1371/journal.pone.0214738

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018 Apr 21;391(10130):1622-36. https://doi.org/10.1016/S0140-6736(18)30481-1

Yamout BI, Alroughani R. Multiple sclerosis. Semin Neurol. 2018 Apr;38(2):212-25. https://doi.org/10.1055/s-0038-1649502

Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016Jan;172(1):3-13. https://doi.org/10.1016/j.neurol.2015.10.006

Walton C, King R, Rechtman L, Kaye W, Leray E, Ann Marrie R, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-21. https://doi.org/10.1177/1352458520970841

Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016 Dec;16(Suppl 6):s53-s59. https://doi.org/10.7861/clinmedicine.16-6-s53

Vasconcelos CCF, Thuler LCS, Rodrigues BC, Calmon AB, Alvarenga RMP. Multiple sclerosis in Brazil: a systematic review. Clin Neurol Neurosurg. 2016 Dec;151:24-30. https://doi.org/10.1016/j.clineuro.2016.07.011

Kobelt G, Teich V, Cavalcanti M, Canzonieri AM. Burden and cost of multiple sclerosis in Brazil. PLoS One. 2019 Jan 23;14(1):e0208837. https://doi.org/10.1371/journal.pone.0208837

Passos GR, Becker J, Varela DL, Fröhlich AC, Rech BC, Mattos ACS, et al. Prevalence of multiple sclerosis in key cities of Brazil: a study in Passo Fundo, Southern Brazil. Arq Neuropsiquiatr. 2021 Aug;79(8):692-6. https://doi.org/10.1590/0004-282X-anp-2020-0221

Marques VD, Passos GR, Mendes MF, Callegaro D, Lana-Peixoto MA, Comini-Frota ER, et al. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arq Neuropsiquiatr. 2018 Aug;76(8):539-54. https://doi.org/10.1590/0004-282X20180078

Baldassari LE, Fox RJ. Therapeutic advances and challenges in the treatment of progressive multiple sclerosis. Drugs. 2018 Oct;78(15):1549-66. https://doi.org/10.1007/s40265-018-0984-5

Gholamzad M, Ebtekar M, Ardestani MS, Azimi M, Mahmodi Z, Mousavi MJ, et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res. 2019 Jan;68(1):25-38. https://doi.org/10.1007/s00011-018-1185-0

Harding-Forrester S, Roos I, Nguyen AL, Malpas CB, Diouf I, Moradi N, et al. Disability accrual in primary and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):707-17. https://doi.org/10.1136/jnnp-2022-330726

Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2017 Oct 19; 11:1789-96. https://doi.org/10.2147/PPA.S142373

Saiz A, Mora S, Blanco J. Cumplimiento terapéutico con terapias modificadoras de la enfermedad de primera línea en pacientes con esclerosis múltiple. Estudio COMPLIANCE. Neurología. 2015 May;30(4):214-22. https://doi.org/10.1016/j.nrl.2013.12.008

Wencel-Warot A, Michalak S, Warot M, Kalinowska-Lyszczarz A, Kazmierski R. The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients. Medicine (Baltimore). 2016 Nov;95(45):e5337. https://doi.org/10.1097/MD.0000000000005337

van Rossum JA, Peters MAD, van der Valk P, de Jong BA. Severe cutaneous adverse event in a daclizumab-treated multiple sclerosis patient. Mult Scler Relat Disord. 2019 Sep;34:38-40. https://doi.org/10.1016/j.msard.2019.06.006

Malta M, Cardoso LO, Bastos FI, Magnanini MMF, Silva CMFP. Iniciativa STROBE: subsídios para a comunicação de estudos observacionais. Rev Saúde Pública. 2010;44(3):559-65. https://doi.org/10.1590/S0034-89102010000300021

Balak DMW, Hengstman GJD, Çakmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012 Dec;18(12):1705-17. https://doi.org/10.1177/1352458512438239

Leal JM, Souza GH, Marsillac PF, Gripp AC. Skin manifestations associated with systemic diseases – Part II. An Bras Dermatol. 2021 Nov-Dec;96(6):672-87. https://doi.org/10.1016/j.abd.2021.06.003

Dantas KM, Lacerda LG, Mendes RF, Coelho VAT, Nascimento ES, Ferraz RL, et al. Esclerose múltipla: eficácia no tratamento por meio de imunomoduladores injetáveis. In: Silva PR. Promoção da saúde: conceito, estratégia e prevenção em pesquisa. 1st ed. São Paulo: Editora Científica Digital; 2023. p. 76–86. https://doi.org/10.37885/230613372

Andrade Andrade I, Tejedor Tejada E, Macías Cortés E, Muñoz Fernández C, Martínez Martínez M. Adherence to treatment with injectable immunomodulators in patients with multiple sclerosis and cognitive disorder. Rev Científica Soc Enferm Neurológica. 2021 July 24;56:11–7. https://doi.org/10.1016/j.sedeng.2021.04.001

Kołtuniuk A, Chojdak-Łukasiewicz J. Adherence to therapy in patients with multiple sclerosis—review. Int J Environ Res Public Health. 2022 Feb 15;19(4):2203. https://doi.org/10.3390/ijerph19042203

Udawatta M, Mateen FJ. Nicolau syndrome following glatiramer acetate for multiple sclerosis: case and review of reports. Ann Clin Transl Neurol. 2024 Apr;11(4):1080-5. https://doi.org/10.1002/acn3.52044

Mozafari N, Saffaei A, Alizadeh M, Shabani M. Cutaneous necrotic lesion: a wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment. J Cosmet Dermatol. 2020 Apr;19(4):951-3. https://doi.org/10.1111/jocd.13104

Maurelli M, Bergamaschi R, Antonini A, Fargnoli MC, Puma E, Mallucci G, et al. Interferon-beta injection site reactions in patients with multiple sclerosis. J Dermatol Treat. 2018 Dec;29(8):831-4. https://doi.org/10.1080/09546634.2018.1467539

Morillo Verdugo R, Ramírez-Herráiz E, Fernández-Del Olmo R, Roig Bonet M, Valdivia García M. Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain. Patient Prefer Adherence. 2019 Feb 13;13:261-72. https://doi.org/10.2147/PPA.S187983

Spessotto CV, Cavalli H, Eboni ACB, Machado RB, Mousquer AM, Palazzo LB, et al. Patients’ satisfaction with and views about treatment with disease- modifying drugs in multiple sclerosis. Arq Neuropsiquiatr. 2016 Aug;74(8):617-20. https://doi.org/10.1590/0004-282X20160091

Hirt PA, Castillo DE, Yosipovitch G, Keri JE. Skin changes in the obese patient. J Am Acad Dermatol. 2019 Nov;81(5):1037-57. https://doi.org/10.1016/j.jaad.2018.12.070

Gil-González I, Martín-Rodríguez A, Conrad R, Pérez-San-Gregorio MA. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020 Nov 30;10(11):e041249. https://doi.org/10.1136/bmjopen-2020-041249

Milstein-Moscati I, Persano S, Castro LLC. Aspectos metodológicos e comportamentais da adesão à terapêutica. In: Castro LLC, org. Fundamentos de farmacoepidemiologia. São Paulo: AG Editora; 2000. p. 171-9.

Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008 Dec;255(suppl 6):87-92. https://doi.org/10.1007/s00415-008-6016-8

Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing- remitting multiple sclerosis. Eur J Neurol. 2011 Jan;18(1):69-77. https://doi.org/10.1111/j.1468-1331.2010.03110.x

Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009 Apr;256(4):568-76. https://doi.org/10.1007/s00415-009-0096-y

Celius EG, Thompson H, Pontaga M, Langdon D, Laroni A, Potra S, et al. Disease progression in multiple sclerosis: a literature review exploring patient perspectives. Patient Prefer Adherence. 2021 Jan 8;15:15-27. https://doi.org/10.2147/PPA.S268829

Yalçın GY, Beser A, Kürtüncü M. Evaluation of the relationship between socio-demographic characteristics and social support with adherence to treatment in patient with multiple sclerosis. Int J Disabil Sports Health Sci. 2022 Dec 20;5(2):75-82. https://doi.org/10.33438/ijdshs.1105516

Machado M, Goulart A, Teich V. Adesão ao tratamento para esclerose múltipla com terapias de primeira linha: análise longitudinal retrospectiva. J Assist Farmac Farmacoecon. 2016 Dec;1(3):10-9. https://doi.org/10.22563/2525-7323.2016.%20v1.n3.p.10-19

Mah J, Thannhauser JE. Management of multiple sclerosis in adolescents- current treatment options and related adherence issues. Adolesc Health Med Ther. 2010 Jun 17;1:31-43. https://doi.org/10.2147/AHMT.S7594

Manso LN. Reações cutâneas provocadas por imunomoduladores injetáveis associadas ao tratamento de esclerose múltipla [dissertação]. Botucatu: Universidade Estadual Paulista Júlio de Mesquita Filho; 2016.